Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jean Pierre Awaida

Interventional Cardiology Delray Beach, FL Medical Doctor

NPI 1508048158 CMS profile 22895

5162 Linton Blvd Ste 102, Delray Beach, FL 33484

Open in the dashboard

General payments

$1,590

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jean Pierre Awaida of Delray Beach, FL is reported in the CMS Open Payments database as having received $1,590 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 17th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49 2
2024 General $281 3
2023 General $208 4
2022 General $277 4
2021 General $238 4
2020 General $91 3
2019 General $446 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jean Pierre Awaida
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jean Pierre Awaida were reported at $49. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jean Pierre Awaida Interventional Cardiology median Middle half National median
2019 $446 $1,097 $329–$3,048 $163
2020 $91 $473 $161–$1,480 $114
2021 $238 $677 $233–$1,827 $132
2022 $277 $978 $333–$2,724 $149
2023 $208 $1,136 $382–$2,986 $160
2024 $281 $1,181 $395–$3,326 $164
2025 $49 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $349 5 payments
  2. Shockwave Medical, Inc $250 2 payments
  3. Astellas Pharma US Inc $198 2 payments
  4. Medtronic, Inc. $155 1 payment
  5. Biosense Webster, Inc. $121 2 payments
  6. Pfizer Inc. $108 1 payment
  7. Boston Scientific Corporation $97 1 payment
  8. HeartFlow, Inc. $74 1 payment
  9. Abiomed $72 2 payments
  10. Terumo Medical Corporation $49 2 payments
  11. Other $116 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,378 23 payments
  2. Education $212 3 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $250 2 payments
  2. Mitra Clip system $157 1 payment
  3. COREVALVE EVOLUT R $155 1 payment
  4. CardioMEMS HF System $142 2 payments
  5. Carto 3 $121 2 payments
  6. VYNDAQEL $108 1 payment
  7. Varithena Administration Pack $97 1 payment
  8. FFRct $74 1 payment
  9. TR Band $49 2 payments
  10. Impella $42 1 payment
  11. Other $244 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

4,817

Median for Cardiology: 2,533

Drug cost

$800,337

Median for Cardiology: $485,213

Branded share of claims

20%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 238 $288,911
Xarelto Rivaroxaban Brand 135 $165,477
Multaq Dronedarone Hcl Brand 56 $80,074
Entresto Sacubitril/Valsartan Brand 57 $67,129
Repatha Sureclick Evolocumab Brand 57 $65,988
Farxiga Dapagliflozin Propanediol Brand 49 $39,749
Jardiance Empagliflozin Brand 24 $30,690
Valsartan Generic 260 $7,600
Metoprolol Succinate Generic 437 $5,185
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 11 $5,099

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$627,908

Of which drugs: $1,431

Medicare patients

1,526

Average age 80

Services billed

7,544

763 women, 763 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Arthritis 60%
Chronic kidney disease 45%
Atrial fibrillation 42%
Diabetes 41%
Depression 38%
Heart failure 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 60 240 $1,368
Infusion, normal saline solution, 250 cc J7050 Office 120 120 $62

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record